drugset / Trial / NCT00192179

A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.

NCT00192179

RandomizedParallel-groupQuadruple-blindPrevention

Summary

A safety study to compare, over a 7 day period, the fever rates following one dose of either Influenza Virus Vaccine or placebo administered outside the influenza season to healthy children and adolescents aged 6 to less than 18 years.

Timeline

Start
2003-06
Primary completion
2003-07
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine 0.2 ml Intranasal

Indications